Key Takeaways & Executive Findings
- •• This correction addresses an overlapping artefact in Fig. 2H of the original article, ensuring data integrity. • The corrected figure is provided to accurately represent the effects of MB-exos on uterine tissue recovery. • The study highlights the role of miR-340-3p-modified BMSC-derived exosomes in inhibiting ferroptosis via METTL3-mediated m6A modification of HMOX1. • These findings support the therapeutic potential of engineered exosomes for uterine injury repair.
Abstract
The original article erroneously presents an overlapping artefact in Fig. 2H; the corrected figure can be viewed ahead in this Correction article.
1. Introduction
This correction article addresses an error in the original publication by Xiao et al. in Stem Cell Research & Therapy (2024) 15:224. The original article erroneously presented an overlapping artefact in Fig. 2H, which could misrepresent the experimental results. The corrected figure is now provided to ensure the accuracy and reliability of the data presented.
The original study investigated the therapeutic effects of miR-340-3p-modified bone marrow mesenchymal stem cell-derived exosomes (MB-exos) on injured rat uterus. The findings demonstrated that MB-exos inhibit ferroptosis through METTL3-mediated m6A modification of HMOX1, thereby promoting uterine recovery. This correction ensures that the visual evidence supporting these conclusions is accurate and reproducible.
Loading authentic research manuscript (Pages 1–5)...
Bang Xiao, Yiqing Zhu, Meng Liu, Meiting Chen, Chao Huang, Dabing Xu, Fang Wang, Shuhan Sun, Jinfeng Huang, Ningxia Sun, Fu Yang (2026). Correction: Mir-340-3p-modified bone marrow mesenchymal stem cell-derived exosomes inhibit ferroptosis through METTL3-mediated m6A modification of HMOX1 to promote recovery of injured rat uterus. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-024-03985-w
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the purpose of this correction article?
This correction article addresses an overlapping artefact in Fig. 2H of the original publication, providing the corrected figure to ensure data accuracy and integrity.
What was the original article about?
The original article investigated the effects of miR-340-3p-modified bone marrow mesenchymal stem cell-derived exosomes on inhibiting ferroptosis via METTL3-mediated m6A modification of HMOX1 to promote recovery of injured rat uterus.
What is the significance of the corrected figure?
The corrected figure accurately represents the hematoxylin and eosin (HE)-stained uterus tissues from different experimental groups, ensuring that the visual evidence supports the study's conclusions.
Who are the corresponding authors of this correction?
The corresponding authors are Jinfeng Huang, Ningxia Sun, and Fu Yang.
What is the DOI of this correction?
The DOI is 10.1186/s13287-024-03985-w.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.